Oncotarget

Research Papers:

Can an IL13 -1112 C/T (rs1800925) polymorphism predict responsiveness to neoadjuvant chemoradiotherapy and survival of Chinese Han patients with locally advanced rectal cancer?

Lin Xiao, Xin Yu, Rong Zhang, Hui Chang, Shaoyan Xi, Weiwei Xiao, Zhifan Zeng, Huizhong Zhang, Ruihua Xu and Yuanhong Gao _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:34149-34157. https://doi.org/10.18632/oncotarget.9178

Metrics: PDF 615 views  |   HTML 790 views  |   ?  


Abstract

Lin Xiao1,2,3,*, Xin Yu1,2,*, Rong Zhang2,4,*, Hui Chang1,2, Shaoyan Xi2,5, Weiwei Xiao1,2, Zhifan Zeng1,2, Huizhong Zhang2,5, Ruihua Xu2,6, Yuanhong Gao1,2

1 Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China

2 State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China

3 Department of Oncology, Section II, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, China

4 Department of Endoscopy and Laser, Sun Yat-sen University Cancer Center, Guangzhou, China

5 Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China

6 Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China

* These authors contributed equally to the paper

Correspondence to:

Yuanhong Gao , email:

Ruihua Xu, email:

Keywords: interleukin-13, single-nucleotide polymorphism, locally advanced rectal cancer, neoadjuvant chemoradiotherapy, prognosis

Received: December 04, 2015 Accepted: April 16, 2016 Published: May 04, 2016

Abstract

We sought to determine whether a polymorphism in the Interleukin 13 gene (IL13), 1112 C/T (rs1800925) predicts responsiveness to neoadjuvant chemoradiotherapy (neoCRT) and prognosis in Chinese Han patients with locally advanced rectal cancer (LARC). Pre-treatment biopsies of primary rectal lesion and surgical specimens were collected from 58 patients with LARC, who were treated with neoCRT and surgery. Tumor DNA was extracted from these biopsies and sequenced to analyze the rs1800925 polymorphism. The tumor response to neoCRT was categorized using a tumor regression grade (TRG, 0-2 were poor responders; 3-4 were good responders). Analyses of progression free survival (PFS) and overall survival (OS) were carried out using the Kaplan-Meier method. Of the forty-six patients for whom tumor DNA was successfully sequenced, 23 were good responders to neoCRT (11 patients with a pathological complete response, i.e. pCR) and the other 23 were poor responders. Good and poor responders were equally likely to have a C/C genotype at rs1800925 (73.9%) as a T/T or C/T genotype (26.1%). There were no differences between the C/C and T/T+C/T genotypes with respect to the ypT0-2 ratio (38.2% vs. 41.7%, P = 1.0) , ypN0 nodal status (67.6% vs. 50.0%, P= 0.314), 6-year PFS (67.6% vs. 50%, P=0.274), or 6-year OS (76.5% vs. 66.7%, P=0.441). Thus, the IL13-1112 C/T (rs1800925) polymorphism does not predict responsiveness to neoCRT or prognosis of Chinese Han patients with LARC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9178